Company Description
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sells of traditional Chinese medicine derivative products in China.
The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule.
In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements.
It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China.
Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
| Country | China |
| Founded | 1998 |
| IPO Date | Mar 23, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Gang Lai |
Contact Details
Address: 265 Jingjiu Avenue, Jinggangshan Eco & Tech Dev Zn Ji'An, 343100 China | |
| Phone | 86 79 6840 3309 |
| Website | universe-pharmacy.com |
Stock Details
| Ticker Symbol | UPC |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001809616 |
| CUSIP Number | G9442G104 |
| ISIN Number | KYG9442G1120 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gang Lai | Chief Executive Officer and Chairman |
| Lin Yang | Chief Financial Officer and Director |
| Baochang Liu | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 26, 2025 | 6-K | Report of foreign issuer |
| Jul 29, 2025 | 6-K | Report of foreign issuer |
| Jul 3, 2025 | 6-K | Report of foreign issuer |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| Apr 29, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 20, 2025 | 6-K | Report of foreign issuer |
| Mar 11, 2025 | 6-K | Report of foreign issuer |
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Feb 25, 2025 | 6-K | Report of foreign issuer |
| Feb 20, 2025 | 6-K | Report of foreign issuer |